Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Cat. No. | Especies | Descripción del producto | Estructura | Pureza | Característica |
|---|---|---|---|---|---|
| DDC-H55H6 | Human | Human DDC / Dopa Decarboxilase Protein, His Tag (MALS verified) |  |
|
The purity of Human DDC, His Tag (Cat. No. DDC-H55H6) is more than 90% and the molecular weight of this protein is around 100-125 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Levodopa/Benserazide Hydrochloride | Approved | F. Hoffmann-La Roche Ltd | Madopar | Switzerland | Parkinson Disease | F. Hoffmann-La Roche Ltd | 1973-06-27 | Parkinson Disease | Details | |
| Eladocagene exuparvovec | PTC-AADC | Approved | National Taiwan University, Ptc Therapeutics Inc | Upstaza | EU | Amino Acid Metabolism, Inborn Errors | Ptc Therapeutics International Ltd | 2022-07-18 | Aromatic amino acid decarboxylase deficiency; Amino Acid Metabolism, Inborn Errors | Details |
| Levodopa/Carbidopa | IPX-066; ABT-SLV-187; ND-0680; ND-0612L; AP-CD/LD; ND-0612; IPX-054; ABT-SLV187; IPX-203; CP-012; AP-09004; DM-1992; AP-CDLD; TPI-926; ND-0612H; PW-4153; LCIG; JM-012; SOL-707; INP-107(POD™ carbidopa/levodopa) | Approved | Merck Sharp & Dohme Corp | Numient, Menesit, Duodopa, Vadova, Sinemet, Rytary, Isicom, Duopa, Flexilev, Nacom (imciromab), Nacom retard, Parcopa, DopaFuse, Patrome | United States | Parkinson Disease; Parkinson Disease, Secondary; Parkinson Disease, Postencephalitic | Merck & Co Inc | 1975-05-02 | Albinism, Oculocutaneous; Diabetes Mellitus; Amyotrophic Lateral Sclerosis; Diabetic Retinopathy; Albinism; Cocaine-Related Disorders; Amblyopia; Depressive Disorder, Treatment-Resistant; Cognitive Dysfunction; Motor Neuron Disease; Aphasia, Broca; Parkinson Disease; Stroke; Parkinson Disease, Postencephalitic; Depression; Parkinson Disease, Secondary; Gait Apraxia | Details |
| Benserazide Hydrochloride | Ro-4-4602 | Approved | Mainland China | Parkinson Disease; Dyskinesias | Shanghai Yishengyuan Pharmaceutical Co Ltd | 1995-01-01 | beta-Thalassemia; Dyskinesias; Parkinson Disease; Anemia, Sickle Cell | Details | ||
| Foslevodopa/Foscarbidopa | ABBV-951 | Approved | Abbvie Inc | VYALEV, Vyalev, Duodopa, Produodopa | Romania, Belgium, Cyprus | Parkinson Disease | Abbvie Deutschland Gmbh & Co Kg, Abbvie Sa, Abbvie Inc | Parkinson Disease | Details | |
| Carbidopa/Entacapone/Levodopa | ELC-200; ODM-101 | Approved | Orion Pharma | Stalevo, LECIGon, Trigel, LECIGel, 达灵复 | United States | Parkinson Disease | Orion Pharma A/S | 2003-06-11 | Parkinson Disease | Details |
| Carbidopa | MK-486 | Approved | Lodosyn | United States | Parkinson Disease | Aton | 1977-04-25 | Postural Orthostatic Tachycardia Syndrome; Parkinson Disease; Orthostatic Intolerance | Details | |
| Carbidopa/Melevodopa | V-1512; GT-1512; CHF-1512; CNP-1512 | Approved | Chiesi Farmaceutici SPA | Sirio | Italy | Parkinson Disease | null | 2003-01-01 | Parkinson Disease | Details |
| Levodopa/Benserazide Hydrochloride | Approved | F. Hoffmann-La Roche Ltd | Madopar | Switzerland | Parkinson Disease | F. Hoffmann-La Roche Ltd | 1973-06-27 | Parkinson Disease | Details | |
| Eladocagene exuparvovec | PTC-AADC | Approved | National Taiwan University, Ptc Therapeutics Inc | Upstaza | EU | Amino Acid Metabolism, Inborn Errors | Ptc Therapeutics International Ltd | 2022-07-18 | Aromatic amino acid decarboxylase deficiency; Amino Acid Metabolism, Inborn Errors | Details |
| Levodopa/Carbidopa | IPX-066; ABT-SLV-187; ND-0680; ND-0612L; AP-CD/LD; ND-0612; IPX-054; ABT-SLV187; IPX-203; CP-012; AP-09004; DM-1992; AP-CDLD; TPI-926; ND-0612H; PW-4153; LCIG; JM-012; SOL-707; INP-107(POD™ carbidopa/levodopa) | Approved | Merck Sharp & Dohme Corp | Numient, Menesit, Duodopa, Vadova, Sinemet, Rytary, Isicom, Duopa, Flexilev, Nacom (imciromab), Nacom retard, Parcopa, DopaFuse, Patrome | United States | Parkinson Disease; Parkinson Disease, Secondary; Parkinson Disease, Postencephalitic | Merck & Co Inc | 1975-05-02 | Albinism, Oculocutaneous; Diabetes Mellitus; Amyotrophic Lateral Sclerosis; Diabetic Retinopathy; Albinism; Cocaine-Related Disorders; Amblyopia; Depressive Disorder, Treatment-Resistant; Cognitive Dysfunction; Motor Neuron Disease; Aphasia, Broca; Parkinson Disease; Stroke; Parkinson Disease, Postencephalitic; Depression; Parkinson Disease, Secondary; Gait Apraxia | Details |
| Benserazide Hydrochloride | Ro-4-4602 | Approved | Mainland China | Parkinson Disease; Dyskinesias | Shanghai Yishengyuan Pharmaceutical Co Ltd | 1995-01-01 | beta-Thalassemia; Dyskinesias; Parkinson Disease; Anemia, Sickle Cell | Details | ||
| Foslevodopa/Foscarbidopa | ABBV-951 | Approved | Abbvie Inc | VYALEV, Vyalev, Duodopa, Produodopa | Romania, Belgium, Cyprus | Parkinson Disease | Abbvie Deutschland Gmbh & Co Kg, Abbvie Sa, Abbvie Inc | Parkinson Disease | Details | |
| Carbidopa/Entacapone/Levodopa | ELC-200; ODM-101 | Approved | Orion Pharma | Stalevo, LECIGon, Trigel, LECIGel, 达灵复 | United States | Parkinson Disease | Orion Pharma A/S | 2003-06-11 | Parkinson Disease | Details |
| Carbidopa | MK-486 | Approved | Lodosyn | United States | Parkinson Disease | Aton | 1977-04-25 | Postural Orthostatic Tachycardia Syndrome; Parkinson Disease; Orthostatic Intolerance | Details | |
| Carbidopa/Melevodopa | V-1512; GT-1512; CHF-1512; CNP-1512 | Approved | Chiesi Farmaceutici SPA | Sirio | Italy | Parkinson Disease | null | 2003-01-01 | Parkinson Disease | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Buspirone/Carbidopa/Levodopa | Phase 2 Clinical | Universite Laval | Spinal Cord Injuries; Multiple Sclerosis | Details | |
| Levodopa/Carbidopa controlled release tablets-night(WD Pharmaceutical) | WD-1905 | Phase 2 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinsonian Disorders | Details |
| Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) | WD-1603 | Phase 2 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinsonian Disorders | Details |
| Levodopa/Carbidopa (Hengrui Medicine) | HRG-2010 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Parkinson Disease | Details |
| Ezaladcigene resoparvovec | VY-AADC; VY-AADC01; GZ-404477; AV-201; VY-AADC02 | Phase 1 Clinical | University Of California, Voyager Therapeutics Inc | Aromatic amino acid decarboxylase deficiency; Parkinson Disease | Details |
| Carbidopa/oxytriptan | EVX-101 | Phase 1 Clinical | Evecxia Therapeutics Inc | Depression | Details |
| VGN-R09 | VGN-R09b; VGN-R09 | Phase 1 Clinical | Shanghai Vitalgen BioPharma Co Ltd | Aromatic amino acid decarboxylase deficiency | Details |
| Levodopa/Carbidopa granule(WD Pharmaceutical) | WD-2010 | Phase 1 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinsonian Disorders | Details |
| Levodopa/Carbidopa(WD Pharmaceutical) | WD-1804 | Phase 1 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinsonian Disorders | Details |
| Buspirone/Carbidopa/Levodopa | Phase 2 Clinical | Universite Laval | Spinal Cord Injuries; Multiple Sclerosis | Details | |
| Levodopa/Carbidopa controlled release tablets-night(WD Pharmaceutical) | WD-1905 | Phase 2 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinsonian Disorders | Details |
| Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) | WD-1603 | Phase 2 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinsonian Disorders | Details |
| Levodopa/Carbidopa (Hengrui Medicine) | HRG-2010 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Parkinson Disease | Details |
| Ezaladcigene resoparvovec | VY-AADC; VY-AADC01; GZ-404477; AV-201; VY-AADC02 | Phase 1 Clinical | University Of California, Voyager Therapeutics Inc | Aromatic amino acid decarboxylase deficiency; Parkinson Disease | Details |
| Carbidopa/oxytriptan | EVX-101 | Phase 1 Clinical | Evecxia Therapeutics Inc | Depression | Details |
| VGN-R09 | VGN-R09b; VGN-R09 | Phase 1 Clinical | Shanghai Vitalgen BioPharma Co Ltd | Aromatic amino acid decarboxylase deficiency | Details |
| Levodopa/Carbidopa granule(WD Pharmaceutical) | WD-2010 | Phase 1 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinsonian Disorders | Details |
| Levodopa/Carbidopa(WD Pharmaceutical) | WD-1804 | Phase 1 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinsonian Disorders | Details |
This web search service is supported by Google Inc.
A-Z
